We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Horizon Discovery Group Plc | HZD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 184.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 184.50 |
| Top Posts |
|---|
Posted at 18/10/2020 09:19 by the stigologist Video explaining Crispr for AIM investors#HZD #MXCT #C4XD |
Posted at 15/10/2020 19:34 by the stigologist Is it a bit too high tech for UK investors to understandI'm v.high I.Q (like well over 80 probably) and even I don't understand it Maybe best they go to the US where there are more specialist tech funds ? |
Posted at 01/8/2020 18:24 by solooiler Yes. Now the covid first half is out of the way the news flow will be around listing progress in the next couple of months I hope which will rev the engine and get investors scrambling to get involved. Here are some annual report quotesIn particular, the Board believes that the U.S. capital markets offer Horizon a larger pool of capital and a broader and deeper investor base in the biotechnology and life science tools sectors, both of which we believe would provide additional trading liquidity in our ordinary shares. Furthermore, listing in the U.S. would allow the Group to accelerate its ‘investing for growth’ strategy which could support further growth in shareholder value. With approximately 50% of our shares already held by U.S. investors at the time of writing, this is a timely move and one the Board has had under review for a considerable time. Q. Is that what is behind the proposed secondary listing in the U.S.? A. Partly. Our Board and advisers firmly believe that the U.S. capital markets would offer Horizon a larger pool of capital and a broader and deeper investor base. Any proceeds raised by the listing process would also allow us to accelerate our ‘investing for growth’ strategy. Q. What sort of reception have you had so far in the U.S.? A. It has been very encouraging. There has been a lot of interest in what we are doing and the feedback suggests that our equity story would have a strong resonance in the U.S. market once we are ready to launch. |
Posted at 31/7/2020 10:22 by solooiler How long until SOMEONE just takes HRZD out. Investors in England dont know what they are valuing. A great British science company that is barely moving because we are a grumbly bunchIt is on less than 3 times sales and these things normally trade on 7x and more! Get that nasdaq listing sorted ASAP |
Posted at 27/6/2020 21:29 by rambutan2 Worth noting that Jeff Ubben left ValueAct last week, although the pieces below says he will/hopes to continue to run the Spring Fund, where HZD is held. We just need HZD to perform like Nikola! |
Posted at 09/6/2020 21:54 by rambutan2 AR says approx 50% of shares held by US insts:Wellington (see post 1351) run a bunch of v large healthcare funds. |
Posted at 07/6/2020 13:18 by solooiler They started filing for it in February but the market volatility delayed it. They will be mental not to reboot the process. They spent £1.7m on it last year too! Annual Report says"Looking forward, Horizon Discovery is pursuing another key strategic shift in the company to dual list on Nasdaq. A secondary listing is driven both by the recognition that the U.S. market plays an increasingly important role in Horizon Discovery’s growth story, and the greater access that it will give Horizon to an American investor base well attuned to growth-oriented life sciences organisations. A dual listing will also have implications for the Directors and the leadership team: evidenced by the recruitment of Dr Siddhartha Kadia, an experienced U.S. Non-Executive Director, who will be appointed shortly after the publication of this report, and the potential for more roles within the executive leadership team to be based in the U.S. over time. " |
Posted at 21/4/2020 08:36 by bouleversee Many investors are up in arms about companies doing these placements which exclude individual shareholders and Share Soc. have organised a petition. If you wish to read about it and sign it you can reach it at:hxxps://allinvestors |
Posted at 04/2/2020 16:49 by jurgenklopp kestlemill,the simple answer is that Americans value such stocks at far higher values than Brits. With an American listing you can see ValueAct engineering some kind of profitable get out like they did with Merlin Entertainment. Plus you have Cathie Wood from ARKinvest really rating the gene editing sub sector as one of her five categories for growth and, in one of the interviews on youtube, she stated that basically, if people understood how gene editing would affect our futures, the three largest US listed shares in the category would be worth nearer $200 billion rather than the $5 billion they are jointly worth now. Normally one can put these statements down as the rantings of a lunatic. However, over the last couple of years she has become rather well known as the person who said that people were valuing Tesla as a motor manufacturer when it should be treated as a high tech stock and, subsequently, set a price target of $4000 on the share. Therefore her opinions in the last week or so have become rather valued and I suspect many investors will start looking at the other sectors she has championed. ValueAct bought their first hefty chunk of HZD at around 214p where they must have seen some value at the time. They are pretty smart cookies too so you can easily see plenty of momentum behind the share price over the next few weeks or months. As a bonus no more involvement from Woodford cannot do any harm either !! |
Posted at 30/12/2019 10:00 by mamcw Found an updated investor presentation on the HZD Investor Resources section of their website dated 14 Dec 2019. It reconfirms 2019 revenue guidance and highlights all the good little things that HZD is doing. However, I'm still waiting for the breakthrough moment, which is why I'm invested in a small cap like HZD. The next results statement really needs to say something special... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
